Millimeter polarisation of the protoplanetary nebula OH 231.8+4.2: A follow-up study with CARMA

In order to investigate the characteristics and influence of the magnetic field in evolved stars, we performed a follow-up investigation of our previous submillimeter analysis of the proto-planetary nebula (PPN) OH 231.8+4.2 (Sabin et al. 2014), this time at 1.3mm with the CARMA facility in polarisation mode for the purpose of a multi-scale analysis. OH 231.8+4.2 was observed at ~2.5" resolution and we detected polarised emission above the 3-sigma threshold (with a mean polarisation fraction of 3.5 %). The polarisation map indicates an overall organised magnetic field within the nebula. The main finding in this paper is the presence of a structure mostly compatible with an ordered toroidal component that is aligned with the PPN's dark lane. We also present some alternative magnetic field configuration to explain the structure observed. These data complete our previous SMA submillimeter data for a better investigation and understanding of the magnetic field structure in OH 231.8+4.2.Comment: 7 pages, 5 figures, 2 tables. Accepted for publication in MNRA

Nuclear Effects on Bremsstrahlung Neutrino Rates of Astrophysical Interest

We calculate in this work the rates for the neutrino pair production by nucleon-nucleon bremsstrahlung taking into account the full contribution from a nuclear one-pion-exchange potential. It is shown that if the temperatures are low enough ($T \leq 20 MeV$), the integration over the nuclear part can be done for the general case, ranging from the completely degenerate (D) to the non-degenerate (ND) regime. We find that the inclusion of the full nuclear contribution enhances the neutrino pair production by $nn$ and $pp$ bremsstrahlung by a factor of about two in both the D and ND limits when compared with previous calculations. This result may be relevant for the physical conditions of interest in the semitransparent regions near the neutrinosphere in type II supernovae, cooling of neutron stars and other astrophysical situations.Comment: 11 pages, no figures, LaTex file. submitted to PR

Evaluating virological outcomes in people with HIV on stable antiretroviral therapy with reduced frequency of HIV viral load monitoring during the COVID-19 pandemic

OBJECTIVE: In response to the COVID-19 pandemic, HIV outpatient attendances were restricted from March 2020, resulting in reduced frequency of HIV viral load (VL) monitoring (previously 6-monthly) in clinically stable and virologically suppressed people living with HIV (PLWH). We investigated virological outcomes during this period of reduced monitoring and compared with the previous year, prior to the COVID-19 pandemic. METHODS: People living with HIV with undetectable VL (<200 HIV RNA copies /mL) on antiretroviral therapy (ART) were identified from March 2018 to February 2019. We determined VL outcomes during the pre-COVD-19 period (March 2019–February 2020) and the COVID-19 period (March 2020–February 2021) when monitoring was restricted. Frequency and longest durations between VL tests in each period were evaluated, and virological sequelae in those with detectable VL were determined. RESULTS: Of 2677 PLWH virologically suppressed on ART (March 2018–February 2019), VLs were measured and undetectable in 2571 (96.0%) and 2003 (77.9%) in the pre-COVID and COVID periods, respectively. Mean (SD) numbers of VL tests were 2.3 (1.08) and 1.1 (0.83) and mean longest duration between VL tests was 29.5 weeks (SD 8.25, 3.1% were ≥12 months) and 43.7 weeks (12.64, 28.4% were ≥12 months), in the pre-COVID and COVID periods, respectively. Of 45 individuals with one or more detectable VL during the COVID-19 period, two developed new drug resistance mutations. CONCLUSION: Reduced VL monitoring was not associated with poorer virological outcomes in the majority of stable individuals receiving ART. One in 20 individuals had not returned for VL testing after ≥31 months and the risk of harm in these individuals is unknown

Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation

No randomized controlled trials have yet reported an individual patient benefit of initiating combination antiretroviral therapy (cART) at CD4 counts > 350 cells/μL. It is hypothesized that earlier initiation of cART in asymptomatic and otherwise healthy individuals may lead to poorer adherence and subsequently higher rates of resistance development

The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations.

OBJECTIVES: We investigated whether age modified associations between markers of HIV progression, CD4 T lymphocyte count and HIV RNA viral load (VL), and the following markers of metabolic function: albumin, haemoglobin, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC). METHODS: A retrospective analysis of data from the United Kingdom Collaborative HIV Cohort was carried out. Analyses were limited to antiretroviral-naïve subjects to focus on the impact of HIV disease itself. A total of 16670 subjects were included in the analysis. Multilevel linear regression models assessed associations between CD4 count/VL and each of the outcomes. Statistical tests for interactions assessed whether associations differed among age groups. RESULTS: After adjustment for gender and ethnicity, there was evidence that lower CD4 count and higher VL were associated with lower TC, LDL-C, haemoglobin and albumin concentrations but higher triglyceride concentrations. Age modified associations between CD4 count and albumin (P 50 years, a 50 cells/μL lower CD4 count correlated with a 2.4 [95% confidence interval (CI) 1.7-3.0], 3.6 (95% CI 3.2-4.0) and 5.1 (95% CI 4.0-6.1) g/L lower haemoglobin concentration and a 0.09 (95% CI 0.07-0.11), 0.12 (95% CI 0.11-0.13) and 0.16 (95% CI 0.13-0.19) g/L lower albumin concentration, respectively. CONCLUSIONS: We present evidence that age modifies associations between CD4 count and plasma albumin and haemoglobin levels. A given reduction in CD4 count was associated with a greater reduction in haemoglobin and albumin concentrations among older people living with HIV. These findings increase our understanding of how the metabolic impact of HIV is influenced by age

The common envelope origins of the fast jet in the planetary nebula M 3-38

We present the analysis of Multi-Espectr\'ografo en GTC de Alta Resoluci\'on para Astronom\'ia (MEGARA) high-dispersion integral field spectroscopic observations of the bipolar planetary nebula (PN) M 3-38. These observations unveil the presence of a fast outflow aligned with the symmetry axis of M 3-38 that expands with a velocity up to $\pm$225 km s$^{-1}$. The deprojected space velocity of this feature can be estimated to be $\approx$320$^{+130}_{-60}$ km s$^{-1}$, which together with its highly collimated morphology suggests that it is one of the fastest jet detected in a PN. We have also used Kepler observations of the central star of M 3-38 to unveil variability associated with a dominant period of 17.7 days. We attribute this to the presence of a low-mass star with an orbital separation of $\approx$0.12-0.16 au. The fast and collimated ejection and the close binary system point towards a common envelope formation scenario for M 3-38.Comment: 9 pages, 5 figures, Accepted ApJ Lette

Virus-induced translational arrest through 4EBP1/2-dependent decay of 5'-TOP mRNAs restricts viral infection

The mosquito-transmitted bunyavirus, Rift Valley fever virus (RVFV), is a highly successful pathogen for which there are no vaccines or therapeutics. Translational arrest is a common antiviral strategy used by hosts. In response, RVFV inhibits two well-known antiviral pathways that attenuate translation during infection, PKR and type I IFN signaling. Despite this, translational arrest occurs during RVFV infection by unknown mechanisms. Here, we find that RVFV infection triggers the decay of core translation machinery mRNAs that possess a 5'-terminal oligopyrimidine (5'-TOP) motif in their 5'-UTR, including mRNAs encoding ribosomal proteins, which leads to a decrease in overall ribosomal protein levels. We find that the RNA decapping enzyme NUDT16 selectively degrades 5'-TOP mRNAs during RVFV infection and this decay is triggered in response to mTOR attenuation via the translational repressor 4EBP1/2 axis. Translational arrest of 5'-TOPs via 4EBP1/2 restricts RVFV replication, and this increased RNA decay results in the loss of visible RNA granules, including P bodies and stress granules. Because RVFV cap-snatches in RNA granules, the increased level of 5'-TOP mRNAs in this compartment leads to snatching of these targets, which are translationally suppressed during infection. Therefore, translation of RVFV mRNAs is compromised by multiple mechanisms during infection. Together, these data present a previously unknown mechanism for translational shutdown in response to viral infection and identify mTOR attenuation as a potential therapeutic avenue against bunyaviral infection

Associations with sub-optimal clinic attendance and reasons for missed appointments among heterosexual women and men living with HIV in London

Poor engagement in HIV care is associated with poorer health outcomes and increased mortality. Our survey examined experiential and circumstantial factors associated with clinic attendance among women (n = 250) and men (n = 106) in London with heterosexually-acquired HIV. While no associations were found for women, among men, sub-optimal attendance was associated with insecure immigration status (25.6% vs. 1.8%), unstable housing (32.6% vs. 10.2%) and reported effect of HIV on daily activities (58.7% vs. 40.0%). Among women and men on ART, it was associated with missing doses of ART (OR = 2.96, 95% CI:1.74-5.02), less belief in the necessity of ART (OR = 0.56, 95% CI:0.35-0.90) and more concern about ART (OR = 3.63, 95% CI:1.45-9.09). Not wanting to think about being HIV positive was the top reason for ever missing clinic appointments. It is important to tackle stigma and the underlying social determinants of health to improve HIV prevention, and the health and well-being of people living with HIV